Previous studies have shown that
ulinastatin, an effective inhibitor of the inflammatory response in clinical applications, can attenuate
hyperalgesia in rodents. However, the underlying mechanism remains unclear. In the present study, we first examined the change in the
calcineurin level, which plays an important role in regulating
cytokine release in the nervous system, following lumbar 5 ventral root transection in the rat. Furthermore, we determined whether intraperitoneal (i.p.) injection of
ulinastatin attenuated
pain behavior via inhibition of the
calcineurin-mediated inflammatory response induced by lumbar 5 ventral root transection. The results showed that the paw withdrawal threshold and paw withdrawal latency were significantly decreased following lumbar 5 ventral root transection compared to the
sham group.
Neuropathic pain induced by lumbar 5 ventral root transection significantly decreased the expression of
calcineurin in the DRG, and
calcineurin was mostly located with NF-200-positive cells, IB4-positive cells, and CGRP-positive cells and less with GFAP-positive satellite cells. Furthermore, intrathecal (i.t.) injection of exogenous
calcineurin attenuated the
pain behavior induced by lumbar 5 ventral root transection. Importantly,
intraperitoneal injection of
ulinastatin alleviated the
pain behavior and
calcineurin downregulation induced by lumbar 5 ventral root transection. Lastly, the
cytokine IL-10 was significantly decreased following lumbar 5 ventral root transection, and application of
calcineurin (intrathecal) or
ulinastatin (intraperitoneal) inhibited the
IL-10 downregulation induced by lumbar 5 ventral root transection. These results suggested that
ulinastatin, by acting on the CN/IL-10 pathway, might be a novel and effective drug for the treatment of
neuropathic pain.